A Phase III randomized, double-blind placebo controlled study of armodafinil (nuvigil®) to reduce cancer-related fatigue in patients with high grade glioma (Alliance A221101)
- Citation:
- J Clin Oncol vol 38 (15_suppl) 12007
- Meeting Instance:
- ASCO 2020
- Year:
- 2020
- Type:
- Abstract
- Sub type:
- Oral
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 3483
- Program:
- CCP
- Primary Committee:
- Symptom Inter
- Sec. Committees:
- Health Outcomes Neuro-Onc
- Pharmas:
- Grants:
- UG1CA189823, U10CA180868 (NRG);
- Corr. Author:
- Authors:
- Alyx B. Porter Sadhna Kohli Jane Cerhan Jeff Sloan Heshan Liu Ryan McMurray Jennifer Le-Rademacher Charles Loprinzi John L. Villano Sani Kizilbash Minesh P. Mehta Kurt Jaeckle Paul D. Brown
- Networks:
- KY010, LAPS-MN026
- Study
- Alliance-A221101
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: